Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0L1CO
|
|||
| Drug Name |
MAGE-A10 TCR
|
|||
| Indication | Bladder cancer [ICD-11: 2C94; ICD-9: 188] | Phase 1/2 | [1] | |
| Head and neck cancer [ICD-11: 2D42] | Phase 1/2 | [1] | ||
| Melanoma [ICD-11: 2C30; ICD-9: 172] | Phase 1/2 | [2] | ||
| Merkel cell carcinoma [ICD-11: 2C34; ICD-10: C44] | Phase 1/2 | [2] | ||
| Company |
Adaptimmune Philadelphia, PA
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | T-cell receptor (TCR) | Target Info | Immunomodulator | [3] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 3 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.